

News Release

Lonza Group Inaugurates New Research and Development Center for South America in Salto, Brazil

Basel (CH) and Salto (BR), 27 February 2018 – Lonza today announced the inauguration of the new Salto Technology Center (STC) in Salto, near São Paulo (BR).

With 1,600 square meters of area, the STC has 13 research laboratories and offers technical services and product applications, which will allow the development of customized solutions for customers in its six business areas of Biosciences, Consumer Health and Nutrition, Hygiene, Coatings and Composites, Agro Ingredients and Water Treatment.

With its laboratories, training/meeting rooms and support facilities, the laboratory complex will serve as a Center of Excellence to share technologies, ingredients, diagnostic systems and knowledge used in these different business units.

Lonza's CEO Richard Ridinger attended the grand opening ceremony in Salto on 26 February 2018. In his speech to the attendees, he said, "The new Salto Technology Center will join our network of Centers of Excellence around the world and enable us to share knowledge that facilitates the development of products and services aligned with the specific needs of the South American market."

He added, "This concept accelerates the process of developing and transferring new technologies and applications to meet an increasingly demanding and dynamic market while still ensuring high quality standards."

Lonza's STC has state-of-the-art infrastructure and equipment, as well as a multidisciplinary team of highly qualified researchers, including chemists, biologists, microbiologists, pharmacists and agronomists who are in partnership with universities and other national and international research centers.

According to Lonza's technology manager responsible for the project, Mauricio Franzim, the initial investment in the STC was BRL 8 million.

"Our goal is to keep new ideas and opportunities flowing regularly through a framework that allows what we call 'cross-pollination,'" Franzim said. "It will be a place where professionals with different skills and experiences can translate quickly and objectively the needs of our clients and then align them with the legislation of each country and Lonza's global health, safety, environment and sustainability policies. In short, we turn molecules and technologies into products and solutions."

One of the STC's laboratories focuses on microbiology, so it was designed and equipped for the manipulation of fungi, bacteria and algae. In conjunction with the laboratory of Analytical Chemistry, the analyses performed there will include Gas Chromatography (GC), High Performance Liquid Chromatography (HPLC), Atomic Absorption Spectrometry (AA), Ultra Violet (UV) spectrometry and a Genetic Sequencing (GS) platform.

The Genetic Sequencing platform, linked to analytical laboratories and applications, is one of the solutions that Lonza offers to diagnose the root cause of microbiological contamination problems and allows monitoring from the manufacturing plant to the consumer market.

About Lonza

Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer's healthy environment.

Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.

Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fast-moving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at www.lonza.com.

Lonza Contact Details

Dirk Oehlers, Head Investor Relations
Lonza Group Ltd
Tel +41 61 316 8540
dirk.oehlers@lonza.com

Dominik Werner, Head Corporate Communications
Lonza Group Ltd
Tel +41 61 316 8798
dominik.werner@lonza.com

Constance Ward, Head External Communications
Lonza Group Ltd
Tel +41 61 316 8840
constance.ward@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.